AR040443A1 - Antagonistas basicos no peptidicos de la bradiquinina y composiciones farmaceuticas de los mismos - Google Patents
Antagonistas basicos no peptidicos de la bradiquinina y composiciones farmaceuticas de los mismosInfo
- Publication number
- AR040443A1 AR040443A1 AR20030102009A ARP030102009A AR040443A1 AR 040443 A1 AR040443 A1 AR 040443A1 AR 20030102009 A AR20030102009 A AR 20030102009A AR P030102009 A ARP030102009 A AR P030102009A AR 040443 A1 AR040443 A1 AR 040443A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- hydrogen atom
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Son compuestos no-peptídicos que tienen actividad como antagonistas específicos del receptor B2 de la bradiquinina (BK). Los compuestos se caracterizan químicamente por la presencia de un aminoácido alfa, alfa-disubstituido, por lo menos un grupo amino, libre o salificado, o la sal de amonio cuaternario correspondiente. Estos antagonistas del receptor BK constituyen una clase novedosa de medicamentos que se pueden utilizar en todos los trastornos en los que están involucrados dichos receptores. Entre las aplicaciones terapéuticas de estos antagonistas pueden citarse: trastornos inflamatorios, alérgicos, autoinmunes tales como el asma y la bronquitis crónica, enfermedades vasomotoras, rinitis viral, enfermedad pulmonar obstructiva, artritis reumatoide, glomerulonefritis, psoriasis, cistitis y algunos trastornos degenerativos caracterizados por fibrosis tales como cirrosis hepática, fibrosis pulmonar y arterioesclerosis. Además ejercen una acción analgésica en el tratamiento del dolor agudo y crónico. Reivindicación 1: Compuestos caracterizados porque responden a la fórmula general (1) donde R1 es un átomo de hidrógeno o un grupo C1-4 alquilo; R2 y R3 que pueden ser iguales o diferentes, son un grupo C1-4 alquilo, o R2 y R3, junto con el átomo de carbono al cual están unidos, forman un grupo alifático cíclico con entre 3 y 7 átomos de carbono o un grupo alifático heterocíclico con entre 3 y 7 átomos, uno o dos de los cuales se seleccionan del grupo N, O, S y los otros son átomos de C; R4 y R5, que pueden ser iguales o diferentes, son un átomo de hidrógeno o un grupo C1-4 alquilo; X se selecciona entre el grupo formado por halógeno, OR1, SR1, CN, C1-4 alquilo; B tiene al menos un grupo amino con características básicas o un grupo tetralquilamonio y se puede seleccionar del grupo formado por: -NR6(CH2)nNHCOY, NR6(CH2)nN(R6)-Y, NR6(CH2)nN(Y)2, NR6Y, N(Y)2, N(Y)(CH2)pY1 y de los residuos seleccionados del grupo de fórmulas (2); R6 es un átomo de hidrógeno, C1-6 alquilo, n = 1-12 e Y se selecciona entre: hidrógeno, (CH2)pY1, (CH2)pNR6Y1, (CH2)pN(Y1)2, NR5R6, -NR6(CH2)qY1 o entre los siguientes residuos seleccionados del grupo de fórmulas (3); T se selecciona entre el grupo de -NR7R8, -NR14R18R19, -OR6; R7 y R8 que pueden ser iguales o diferentes, son un átomo de hidrógeno, un grupo C1-4 alquilo, un grupo ciclohexilo, o NR7R8 juntos son un grupo seleccionado entre 1) guanidina opcionalmente sustituida con 1 o 2 grupos C1-4 alquilo o ciclohexilo, 2) heterociclo con nitrógeno de 5-7 miembros que contiene opcionalmente otro heteroátomo seleccionado entre O, N, S; Y1 se selecciona entre el grupo formado por NR7R8, NR14R18R19 o entre los siguientes residuos del grupo de fórmulas (4); Z se selecciona entre el grupo formado por H, C1-6 alquilo, OR6, SR6, CF3, OCOR6, COR10, NHCOR6, SO2R6, SOR6, CO2R6, N(R6)2, Cl, Br, NO2, NH2, CN, F, imidazol, fenilo, amidina, guanidina, guanidil-metilo; R9 se selecciona entre el grupo formado por hidrógeno, -(CH2)q-L, donde L se selecciona entre el grupo de -OH, -NR5R6, -NR14R18R19, amidina opcionalmente sustituida con 1 o 2 grupos C1-4 alquilo; guanidina opcionalmente sustituida con 1 ó 2 grupos C1-4 alquilo; R10 se selecciona entre el grupo formado por OR6, NR6R12; R11 se selecciona entre el grupo formado por hidrógeno, -(CH2)q-L, -(CH2)p-NR4-(CH2)q-L; R12 es un átomo de hidrógeno, C1-6 alquilo, COR6, R13 se selecciona entre el grupo formado por H, C1-6 alquilo, -(CH2)pW(CH2)qY1, Y, -COY, -CH2-Y; R15 se selecciona entre el grupo formado por hidrógeno o grupos C1-4 alquilo lineales o ramificados; el grupo -NR16R17 es un heterociclo alifático con nitrógeno de 5-6 miembros que contiene opcionalmente otro heteroátomo seleccionado entre O, S, N; el grupo -NR14R18R19 es un grupo de amonio cuaternario en el cual R14 se selecciona entre el grupo formado por grupos C1-4 alquilo lineales o ramificados, R18 y R19 que pueden ser iguales o diferentes, son un grupo C1-4 alquilo lineal o ramificado, o -NR18R19 es un heterociclo con nitrógeno de 5-7 miembros que contiene opcionalmente otro heteroátomo seleccionado entre O, N, S; W = CH2, O, S, NR4, N(R4)2, p = 1-6, q = 1-6; y las sales aceptables para uso farmacológico de los mismos con ácidos inorgánicos u orgánicos seleccionados del grupo de ácidos clorhídrico, bromhídrico, yodhídrico, sulfúrico, fosfórico, acético, trifluoroacético, propiónico, oxálico, málico, maleico, succínico, malónico, aspártico, glutámico y sus posibles isómeros ópticos o sus mezclas, incluyendo los racematos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002MI001247A ITMI20021247A1 (it) | 2002-06-07 | 2002-06-07 | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040443A1 true AR040443A1 (es) | 2005-04-06 |
Family
ID=29727266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20030102009A AR040443A1 (es) | 2002-06-07 | 2003-06-05 | Antagonistas basicos no peptidicos de la bradiquinina y composiciones farmaceuticas de los mismos |
Country Status (23)
Country | Link |
---|---|
US (1) | US7491825B2 (es) |
EP (1) | EP1513531B1 (es) |
JP (1) | JP4293988B2 (es) |
CN (1) | CN1658877B (es) |
AR (1) | AR040443A1 (es) |
AT (1) | ATE446091T1 (es) |
AU (1) | AU2003242628A1 (es) |
BR (1) | BR0311825A (es) |
CA (1) | CA2488565C (es) |
CY (1) | CY1109543T1 (es) |
DE (1) | DE60329755D1 (es) |
DK (1) | DK1513531T3 (es) |
EG (1) | EG26672A (es) |
ES (1) | ES2332509T3 (es) |
IT (1) | ITMI20021247A1 (es) |
MX (1) | MXPA04012193A (es) |
PL (1) | PL224990B1 (es) |
PT (1) | PT1513531E (es) |
RU (1) | RU2327688C2 (es) |
SA (1) | SA03240198B1 (es) |
SI (1) | SI1513531T1 (es) |
TW (1) | TWI315983B (es) |
WO (1) | WO2003103671A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ535889A (en) * | 2002-03-26 | 2006-03-31 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP4619786B2 (ja) * | 2002-08-29 | 2011-01-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性、アレルギー性及び増殖性疾患の治療において糖質コルチコイドミメティックスとして使用するための3−(スルホンアミドエチル)−インドール誘導体 |
UY28526A1 (es) * | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
US7795272B2 (en) * | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
PE20060776A1 (es) * | 2004-12-27 | 2006-09-26 | Boehringer Ingelheim Pharma | Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas |
WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
CA2666406A1 (en) | 2006-10-16 | 2008-04-24 | Gruenenthal Gmbh | Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators |
JP2010512331A (ja) * | 2006-12-06 | 2010-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用 |
TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽b2受體調節劑 |
EP2136634A4 (en) * | 2007-04-10 | 2011-07-06 | Boehringer Ingelheim Int | MIMETIC GLUCOCORTICOID SUBSTANCES, PREPARATION METHODS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
ITMI20072225A1 (it) * | 2007-11-23 | 2009-05-24 | Luso Farmaco Inst | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
CA2726449A1 (en) * | 2008-06-06 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
IT1391236B1 (it) * | 2008-07-11 | 2011-12-01 | St Luso Farm D'italia Spa | Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso |
EP3998259A1 (en) | 2017-11-24 | 2022-05-18 | Pharvaris Netherlands B.V. | Novel bradykinin b2 receptor antagonists |
AR118982A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
AR118983A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
WO2023180577A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Therapeutic uses of bradykinin b2-receptor antagonists |
WO2023180575A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽b2受體拮抗劑之固態延長釋放組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2735128B1 (fr) * | 1995-06-07 | 1997-07-25 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique. |
DE19609827A1 (de) * | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
DE19610784A1 (de) * | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
FR2751650B1 (fr) | 1996-07-24 | 1998-10-09 | Fournier Ind & Sante | Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique |
FR2756562B1 (fr) * | 1996-12-04 | 1999-01-08 | Fournier Ind & Sante | Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique |
DE19712960A1 (de) * | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
-
2002
- 2002-06-07 IT IT2002MI001247A patent/ITMI20021247A1/it unknown
-
2003
- 2003-06-04 EG EG2003060535A patent/EG26672A/en active
- 2003-06-05 MX MXPA04012193A patent/MXPA04012193A/es active IP Right Grant
- 2003-06-05 PL PL373466A patent/PL224990B1/pl unknown
- 2003-06-05 CN CN038130270A patent/CN1658877B/zh not_active Expired - Fee Related
- 2003-06-05 BR BR0311825-8A patent/BR0311825A/pt not_active Application Discontinuation
- 2003-06-05 US US10/516,681 patent/US7491825B2/en not_active Expired - Fee Related
- 2003-06-05 WO PCT/EP2003/005893 patent/WO2003103671A1/en active Application Filing
- 2003-06-05 EP EP03757025A patent/EP1513531B1/en not_active Expired - Lifetime
- 2003-06-05 JP JP2004510790A patent/JP4293988B2/ja not_active Expired - Fee Related
- 2003-06-05 ES ES03757025T patent/ES2332509T3/es not_active Expired - Lifetime
- 2003-06-05 TW TW092115212A patent/TWI315983B/zh not_active IP Right Cessation
- 2003-06-05 PT PT03757025T patent/PT1513531E/pt unknown
- 2003-06-05 SI SI200331698T patent/SI1513531T1/sl unknown
- 2003-06-05 AT AT03757025T patent/ATE446091T1/de active
- 2003-06-05 AR AR20030102009A patent/AR040443A1/es not_active Application Discontinuation
- 2003-06-05 DE DE60329755T patent/DE60329755D1/de not_active Expired - Lifetime
- 2003-06-05 AU AU2003242628A patent/AU2003242628A1/en not_active Abandoned
- 2003-06-05 DK DK03757025.6T patent/DK1513531T3/da active
- 2003-06-05 RU RU2004135567/04A patent/RU2327688C2/ru not_active IP Right Cessation
- 2003-06-05 CA CA2488565A patent/CA2488565C/en not_active Expired - Fee Related
- 2003-07-12 SA SA3240198A patent/SA03240198B1/ar unknown
-
2009
- 2009-12-03 CY CY20091101272T patent/CY1109543T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA04012193A (es) | 2005-02-25 |
CY1109543T1 (el) | 2014-08-13 |
WO2003103671A8 (en) | 2004-12-29 |
DK1513531T3 (da) | 2010-01-18 |
US20060205712A1 (en) | 2006-09-14 |
CA2488565C (en) | 2012-01-03 |
JP2005532354A (ja) | 2005-10-27 |
ITMI20021247A1 (it) | 2003-12-09 |
DE60329755D1 (de) | 2009-12-03 |
PT1513531E (pt) | 2009-12-17 |
SI1513531T1 (sl) | 2010-01-29 |
SA03240198B1 (ar) | 2009-12-08 |
EP1513531A1 (en) | 2005-03-16 |
CN1658877B (zh) | 2010-04-28 |
ES2332509T3 (es) | 2010-02-08 |
RU2004135567A (ru) | 2005-07-20 |
EG26672A (en) | 2014-05-13 |
EP1513531B1 (en) | 2009-10-21 |
RU2327688C2 (ru) | 2008-06-27 |
ATE446091T1 (de) | 2009-11-15 |
CA2488565A1 (en) | 2003-12-18 |
WO2003103671A1 (en) | 2003-12-18 |
AU2003242628A1 (en) | 2003-12-22 |
TW200400819A (en) | 2004-01-16 |
BR0311825A (pt) | 2005-03-15 |
TWI315983B (en) | 2009-10-21 |
CN1658877A (zh) | 2005-08-24 |
PL373466A1 (en) | 2005-09-05 |
JP4293988B2 (ja) | 2009-07-08 |
US7491825B2 (en) | 2009-02-17 |
PL224990B1 (pl) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040443A1 (es) | Antagonistas basicos no peptidicos de la bradiquinina y composiciones farmaceuticas de los mismos | |
AR057815A1 (es) | Acidos propanoicos sustituidos por 3-(4-hidroxi-fenilo) con restricciones conformacionales que resultan de utilidad para el tratamiento de trastornos metabolicos | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR017236A1 (es) | Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar | |
CY1105899T1 (el) | Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες | |
TW200635585A (en) | Monocyclic substituted methanones | |
HRP20080120T3 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
PE20020220A1 (es) | Compuestos de nitrilo de dipeptido como inhibidores de catepsina k | |
PE20070593A1 (es) | Compuestos pirrolopirimidina como inhibidores de syk | |
ES2592713T3 (es) | Derivados de indazolil-triazol como inhibidores de IRAK | |
RS51204B (sr) | Heterociklični supstituisani fenil metanoni kao inhibitori glicin transportera 1 | |
ATE496043T1 (de) | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren | |
PE20081385A1 (es) | Derivados de nicotinamida | |
PE20040780A1 (es) | Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
PE20050991A1 (es) | Derivados de benceno sulfonamida | |
PE20100093A1 (es) | Derivados de acetileno | |
PE20060076A1 (es) | Antagonistas del receptor de acetilcolina muscarinico | |
PE20061207A1 (es) | Derivados de bifenil-piperidina como antagonistas de receptores muscarinicos | |
AR061647A1 (es) | Inhibidores de cxcr2 y sus composiciones farmaceuticas | |
PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
EA200500777A1 (ru) | Производные 3-(3,5-диоксо-4,5-дигидро-3h-(1,2,4)триазин-2-ил)бензамида в качестве ингибиторов p2xдля лечения воспалительных заболеваний | |
IT1231413B (it) | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht | |
PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
PE20040755A1 (es) | Compuestos tipo diarilureas fluoradas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |